Direct Flow Medical prosthesis is a nonmetallic, repositionable, recaptured valve (even after posts dilate), that does not require a pacemakers use during both implantation and post-dilatation.  The aim of this study was to evaluate new valve results to one year in patients with symptomatic severe aortic stenosis with 19 and 26 mm ring, EuroScore of...

This record has been created in order to evaluate the results of percutaneous aortic valve replacement in the UK and currently includes more than 4500 patients with 100% follow-up for mortality. The 3-year mortality was 61.6 % beyond the device or path. Atrial fibrillation, renal failure, chronic obstructive pulmonary disease and a EuroSCORE > 18.5...

The Cadiobrand device is implanted through a transseptal approach and makes a reduction in the mitral annulus area. The study included 24 patients with moderate mitral regurgitation (functional class III- IV) and high surgical risk. The device was successfully implanted in all cases reducing the annular size by 92 % and to the same extent...

Severe mitral regurgitation is three times more prevalent than aortic stenosis in the elderly population at high risk and poor prognosis if not treated. Fortis mitral valve was designed using several preclinical models and are now tested for the first time in 4 patients resulting in various technical difficulties and finally the death of 3...

Presentation Summary: ACCESS-EUROPE multicenter registry included 567 patients with severe mitral regurgitation treated with Mitral Clip in 14 European centers. Procedural success was high, (99.6%), while the 30-day mortality rate, (3.4%) and the one year rate, (18.2%) was acceptable. Annual mortality was more pronounced in those patients with a EuroSCORE greater than 20%, (76.3% vs....

The PARTNER Cohort A randomized 699 elderly patients, (mean age 84.1), with severe aortic stenosis for TAVI or conventional surgery in 26 centers. The group of patients who received TAVI was divided into two groups: trans-femoral procedure, (244 patients), or trans-apical procedure, (104 patients). After one year mortality was similar but stroke and transient ischemic...

Alan Wilson and Szeto Zajarias show that vascular complications of the trans-femoral path remain an important factor because of the high profile of the catheters used in TAVI and the appearance of smaller devices, as well as the experience of surgeons, will progressively reduce complication rates.  Josep Rodes-Cabau commented about the negative impact a stroke...

We evaluated 88 consecutive patients (at this phase) with severe aortic stenosis who received the second-generation device for transapical access. Survival at thirty days was 85.1% with a cardiovascular death rate of 4.8%. No strokes were observed during this period. Average gradient reduction was highly significant, (40.4 to 8.1 mmHg, p <0.001), as well as...

The aim of this study was to evaluate the safety and efficacy of the new device in patients with severe aortic stenosis at high surgical risk. We included 120 patients with a mean age of 84 years and the aortic valve area of 0.7 cm2. The device was successfully implanted in all patients with a...

Percutaneous aortic valve implantation ( TAVI ) recently demonstrated its superiority over medical treatment in patients with severe aortic stenosis and high surgical risk. Furthermore patients receiving TAVI showed a survival surgery equivalent to one year. This study included 471 patients with symptomatic severe aortic stenosis discarded of surgery due  a very high risk. The...